Bristol-Myers Squibb Company (BMY) Third Quarter Featured Solid Operating Performance, Robust Clinical Data and the Strategic Acquisition of ZymoGenetics, Inc. (ZGEN)
10/26/2010 9:39:13 AM
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.
comments powered by